Trials / Conditions / IDH2 Gene Mutation

IDH2 Gene Mutation

10 registered clinical trials studyying IDH2 Gene Mutation — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Niraparib In Recurrent IDH 1/2 Gliomas NCT05406700	Massachusetts General Hospital	EARLY_Phase 1
Withdrawn	A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neopla NCT04955938	University of Chicago	Phase 1
Terminated	Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers NCT04092179	University Health Network, Toronto	Phase 1 / Phase 2
Completed	IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT NCT04522895	Heinrich-Heine University, Duesseldorf	Phase 2
Withdrawn	Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation NCT03881735	Roswell Park Cancer Institute	Phase 2
Active Not Recruiting	BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas NCT03749187	University of California, San Francisco	Phase 1
Recruiting	Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 G NCT03683433	M.D. Anderson Cancer Center	Phase 2
Terminated	Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis NCT03303950	University of Utah	Phase 2
Recruiting	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome NCT03383575	M.D. Anderson Cancer Center	Phase 2
Unknown	Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia NCT04369287	Istituto Clinico Humanitas	—